This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-histone IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the histone as well as the biological activity of IL2. The recombinant IL-2/anti-DNA fusion protein, was developed with the aim of maximizing immunomodulatory action and clinical efficacy at minimal vascular toxicity, despite treatment at optimal doses. The analysis of peripheral leukocytes showed a strong and transitory increase early after infusion of IL-2/anti-DNA fusion protein. lymphocytes responded readily while the effects on monocytes were less pronounced, and no significant changes were observed to neutrophils. This immunocytokine was designed for treating necrotic tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH114. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.